CRISPR Therapeutics AGCRSP +1.74%41 Forward Dividend Yield % is 0.00% as of Jun. 27, 2026. GuruFocus rates CRSP with a GF Score™ of 41/100 and a GF Value™ of $2.44 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 146 Biotechnology companies, CRISPR Therapeutics AG ranks worse than 684930.82% on this metric.
As of today (2026-06-27), the Forward Annual Dividend Yield of CRISPR Therapeutics AG is 0.00%.
As of today (2026-06-27), the Trailing Annual Dividend Yield of CRISPR Therapeutics AG is 0.00%.
CRSP's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.525 * Ranked among companies with meaningful Forward Dividend Yield % only.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
CRISPR Therapeutics AG (NAS:CRSP) Forward Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
CRISPR Therapeutics AG Forward Dividend Yield % Related Terms
CRSP vs CGON, XENE, DNTH: Forward Dividend Yield % Comparison
For the Biotechnology subindustry, CRISPR Therapeutics AG's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CRISPR Therapeutics AG Forward Dividend Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CRISPR Therapeutics AG's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where CRISPR Therapeutics AG's Forward Dividend Yield % falls into.
What does a Forward Dividend Yield % of 0.00% mean?
CRISPR Therapeutics AG (CRSP) has a Forward Dividend Yield % of 0.00% as of Jun. 27, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on CRISPR Therapeutics AG and its competitors. According to the industry distribution chart, CRISPR Therapeutics AG ranks #999999 out of 146 companies in the Biotechnology industry.
Is CRISPR Therapeutics AG's Forward Dividend Yield % too high?
CRISPR Therapeutics AG's current Forward Dividend Yield % is 0.00%. Based on the distribution chart, CRISPR Therapeutics AG ranks #999999 out of 146 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, CRISPR Therapeutics AG has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CRISPR Therapeutics AG's Forward Dividend Yield % compare to CGON and XENE?
According to the Biotechnology industry distribution chart, CRISPR Therapeutics AG ranks #999999 out of 146 companies for Forward Dividend Yield %. This places CRISPR Therapeutics AG in the lower half of its industry. The industry median Forward Dividend Yield % is 1.53. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Biotechnology company?
The median Forward Dividend Yield % among Biotechnology companies is 1.53, based on 146 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on CRISPR Therapeutics AG and its competitors. For the Biotechnology industry, the median Forward Dividend Yield % is 1.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CRISPR Therapeutics AG's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CRISPR Therapeutics AG stock overvalued right now?
Based on GuruFocus' analysis, CRISPR Therapeutics AG (CRSP) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.44, compared to a current price of $54.92 — trading 2150.8% above its estimated fair value. The current Forward Dividend Yield % is 0.00%. CRISPR Therapeutics AG's overall GF Score™ is 41/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For CRISPR Therapeutics AG (CRSP), the current Forward Dividend Yield % is 0.00% as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CRISPR Therapeutics AG (CRSP) Overvalued in 2026?
Based on GuruFocus' analysis, CRISPR Therapeutics AG stock appears to be overvalued.
The current stock price of $54.92 is trading 2150.8% above its estimated GF Value™ of $2.44.
GuruFocus considers CRISPR Therapeutics AG to be Significantly Overvalued.
Key valuation signals for CRSP:
Forward Dividend Yield %: 0.00%
GF Value™: $2.44 vs. price of $54.92 (2150.8% above fair value)
No single metric tells the full story. See the CRSP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
41GF Score
Get the complete analysis for CRSP
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CRSP has been successfully added to your 